Idera Pharmaceuticals Highlights Presentation Of ILLUMINATE-101 Data Demonstrating Tilsotolimod Activates Innate and Adaptive Immunity as Monotherapy in Patients with Refractory Solid Tumors At AACR 2019 Annual Meeting
Benzinga Newsdesk